Enhanced release of sphingosine-1-phosphate from hypercholesterolemic platelets: Role in development of hypercholesterolemic atherosclerosis

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 78, Issue 6, 2008, Pages 383-390

  Son, Dong Ju ^a,b   Lee, Hyoung Woo ^a   Shin, Hyun Woo ^a   Lee, Jung Jin ^a   Yoo, Hwan Soo ^a   Kim, Tack Joong ^c   Yun, Yeo Pyo ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b UNIVERSITY OF IOWA   (United States)

^c Yonsei University Wonju   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EDG 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SPHINGOSINE 1 PHOSPHATE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CHOLESTEROL INTAKE; CONTROLLED STUDY; DISEASE COURSE; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; AORTA, THORACIC; ARACHIDONIC ACID; ATHEROSCLEROSIS; BLOOD PLATELETS; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COLLAGEN; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; LYSOPHOSPHOLIPIDS; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLATELET AGGREGATION; RABBITS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; THROMBIN; TRIGLYCERIDES;

ORYCTOLAGUS CUNICULUS;

EID: 46049118194     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2008.04.010     Document Type: Article

References (43)

1. Siess W. Molecular mechanisms of platelet activation. Physiol. Rev. 69 (1989) 58-178
2. van Zanten G.H., de Graaf S., Slootweg P.J., Heijnen H.F., Connolly T.M., and de Groot P.G. Increased platelet deposition on atherosclerotic coronary arteries. J. Clin. Invest. 93 (1994) 615-632
3. Ross R., Raines E.W., and Bowen-Pope D.F. The biology of platelet-derived growth factor. Cell 46 (1986) 155-169
4. Jankowski J., Hagemann J., Yoon M.S., van der Giet M., Stephan N., Zidek W., Schluter H., and Tepel M. Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. Kidney Int. 59 (2001) 1134-1141
5. 2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovasc. Radiat. Med. 5 (2004) 20-26
6. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Serotonin potentiates angiotensin II-induced vascular smooth muscle cell proliferation. Atherosclerosis 159 (2001) 269-279
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
8. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
9. Tanimoto T., Lungu A.O., and Berk B.C. Sphingosine 1-phosphate transactivates the platelet-derived growth factor beta receptor and epidermal growth factor receptor in vascular smooth muscle cells. Circ. Res. 94 (2004) 1050-1058
10. Xu C.B., Hansen-Schwartz J., and Edvinsson L. Sphingosine signaling and atherogenesis. Acta Pharmacol. Sin. 25 (2004) 849-854
11. Igarashi Y. Functional roles of sphingosine, sphingosine 1-phosphate, and methylsphingosine: in regard to membrane sphingolipid signaling pathways. J. Biol. Chem. 122 (1997) 1080-1087
12. Kluk M., and Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim. Biophys. Acta 1582 (2002) 72-80
13. Usui S., Sugimoto N., Takuwa N., et al. Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J. Biol. Chem. 279 (2004) 12300-12311
14. Auge N., Nikolova-Karakashian M., Carpentier S., et al. Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase ceramidase, and sphingosine kinase. J. Biol. Chem. 274 (1999) 21533-21538
15. Auge N., Garcia V., Maupas-Schwalm F., Levade T., Salvayre R., and Negre-Salvayre A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1990-1995
16. Gouni-Berthold I., and Sachinidis A. Does the coronary risk factor low density lipoprotein alter growth and signaling in vascular smooth muscle cells?. FASEB J. 16 (2002) 1477-1487
17. Carvalho A.C.A., Colman R.W., and Lees R.S. Platelet function in hyperlipoproteinemia. N. Engl. J. Med. 290 (1974) 434-438
18. 2 formation. Arterioscler. Thromb. 14 (1994) 1379-1385
19. Reilly M.P., Taylor S.M., Franklin C., et al. Prothrombotic factors enhance heparin-induced thrombocytopenia and thrombosis in vivo in a mouse model. J. Thromb. Haemost. 4 (2006) 2687-2694
20. Shanmuganayagam D., Warner T.F., Krueger C.G., Reed J.D., and Folts J.D. Concord grape juice attenuates platelet aggregation, serum cholesterol and development of atheroma in hypercholesterolemic rabbits. Atherosclerosis 190 (2007) 135-142
21. Lim Y., Kim T.J., Jin Y.R., et al. Epothilone B inhibits neointimal formation after rat carotid injury through the regulation of cell cycle-related proteins. J. Pharmacol. Exp. Ther. 321 (2007) 648-655
22. Son D.J., Cho M.R., Jin Y.R., et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostagland. Leukot. Essent. Fatty Acids 71 (2004) 25-31
23. Burenjargal M., Lee Y.S., Yoo J.M., et al. Endogenous sphingolipid metabolites related to the growth in Sphingomonas chungbukensis. Arch. Pharm. Res. 30 (2007) 317-322
24. Son D.J., Ha S.J., Song H.S., et al. Melittin inhibits vascular smooth muscle cell proliferation through induction of apoptosis via suppression of nuclear factor-kappaB and Akt activation and enhancement of apoptotic protein expression. J. Pharmacol. Exp. Ther. 317 (2006) 627-634
25. Cassar K., Bachoo P., and Brittenden J. The role of platelets in peripheral vascular disease. Eur. J. Vasc. Endovasc. Surg. 25 (2003) 6-15
26. de Lorgeril M., Boissonnat P., Mamelle N., et al. Platelet aggregation and HDL cholesterol are predictive of acute coronary events in heart transplant recipients. Circulation 89 (1994) 2590-2594
27. Relou I.A., Hackeng C.M., Akkerman J.W., and Malle E. Low-density lipoprotein and its effect on human blood platelets. Cell Mol. Life Sci. 60 (2003) 961-971
28. Murata N., Sato K., Kon J., et al. Interaction of sphingosine 1-phosphate with plasma components including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 352 (2000) 809-815
29. Tamama K., Kon J., Sato K., et al. Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA synthesis and migration of rat aortic smooth-muscle cells. Biochem. J. 353 (2001) 139-146
30. Alewijnse A.E., and Peters S.L. Sphingolipid signaling in the cardiovascular system: good bad or both?. Eur. J. Pharmacol. 585 (2008) 292-302
31. Assmann G., and Nofer J.R. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med. 54 (2003) 321-341
32. Kimura T., Sato K., Kuwabara A., et al. Sphindgosine-1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276 (2001) 31780-31785
33. Argraves K.M., and Argraves W.S. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res. 48 (2007) 2325-2333
34. Nofer J.R., Walter M., and Assmann G. Current understanding of the role of high-density lipoprotein in atherosclerosis and senescence. Expert. Rev. Cardiovasc. Ther. 3 (2005) 1071-10869
35. Uittenbogaard A., Shaul P.W., Yuhanna I.S., Blair A., and Smart E.J. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J. Biol. Chem. 275 (2000) 11278-11283
36. Yuhanna I.S., Zhu Y., Cox B.E., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7 (2001) 853-857
37. Yatomi Y., Igarashi Y., Yang L., et al. Sphingosin-1-phosphate a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J. Biochem. 121 (1997) 969-973
38. Yang L., Yatomi Y., Miura Y., Satoh K., and Ozaki Y. Metabolism and functional effects of sphingolipids in blood cells. Br. J. Haematol. 107 (1999) 282-293
39. Yatomi Y., Ozaki Y., Ohmori T., and Igarashi Y. Sphingosine 1-phosphate: synthesis and release. Prostagland. Other Lipid Mediat. 64 (2001) 107-122
40. Garcia J.G., Liu F., Verin A.D., et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 108 (2001) 689-701
41. Dudek S.M., Jacobson J.R., Chiang E.T., et al. Pulmonary endothelial cell barrier enhancement by Sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J. Biol. Chem. 179 (2004) 24692-24700
42. Singleton P.A., Dudek S.M., Chiang E.T., and Garcia J.G. Regulation of Sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase Tiam1/Rac1, and alpha-actinin. FASEB J. 19 (2005) 1646-1656
43. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115 (2007) 84-105